Key Points
- Kymera Therapeutics Director Bruce Booth sold 115,056 shares on June 18 at an average price of $91.01, totaling about $10.47 million. The trade was disclosed in an SEC filing and was made under a pre-arranged Rule 10b5-1 plan.
- Booth has been actively selling shares recently, including multiple large transactions in June that brought his total recent sales well above $40 million. After the June 18 sale, he still directly owned 647,914 shares worth about $58.97 million.
- Kymera’s stock has been strong despite the insider selling, recently trading near $99.45 with a 52-week range of $36.65 to $105.00. The company also beat quarterly expectations, posting smaller-than-expected losses and revenue of $34.37 million, well above analyst estimates.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Noah Goodman sold 2,500 shares of the company's stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $99.00, for a total transaction of $247,500.00. Following the sale, the insider owned 50,195 shares of the company's stock, valued at approximately $4,969,305. The trade was a 4.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Noah Goodman also recently made the following trade(s):
- On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.00, for a total value of $121,230.00.
- On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.35, for a total transaction of $174,700.00.
- On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total transaction of $723,100.00.
Kymera Therapeutics Price Performance
NASDAQ KYMR opened at $99.45 on Tuesday. The stock has a market capitalization of $8.18 billion, a PE ratio of -27.86 and a beta of 2.02. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $105.00. The business's 50-day moving average is $83.41 and its 200 day moving average is $81.31.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analysts' expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business's revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.82) earnings per share. As a group, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.
Institutional Trading of Kymera Therapeutics
Several hedge funds have recently bought and sold shares of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company's stock worth $849,000 after buying an additional 1,833 shares in the last quarter. Millennium Management LLC increased its position in Kymera Therapeutics by 340.4% during the first quarter. Millennium Management LLC now owns 510,480 shares of the company's stock valued at $13,972,000 after acquiring an additional 394,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock worth $24,535,000 after acquiring an additional 491,737 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Kymera Therapeutics by 13.8% during the second quarter. Invesco Ltd. now owns 47,884 shares of the company's stock valued at $2,090,000 after purchasing an additional 5,809 shares during the period. Finally, Sei Investments Co. purchased a new stake in Kymera Therapeutics in the 2nd quarter valued at about $265,000.
Analysts Set New Price Targets
A number of research analysts recently issued reports on KYMR shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen raised Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 2nd. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a report on Monday, June 8th. Piper Sandler boosted their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, February 26th. Finally, BTIG Research reduced their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating for the company in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $117.14.
View Our Latest Report on KYMR
Key Kymera Therapeutics News
Here are the key news stories impacting Kymera Therapeutics this week:
- Positive Sentiment: Kymera previously reported quarterly results that beat expectations, with EPS of ($0.71) versus consensus of ($0.89) and revenue of $34.37 million versus estimates of $8.27 million, which supports the bullish long-term thesis.
- Neutral Sentiment: The insider sales were made under pre-arranged Rule 10b5-1 trading plans, which can reduce concern that the transactions reflect a sudden change in outlook.
- Negative Sentiment: Director Bruce Booth sold multiple large blocks of KYMR shares in recent days, including a $24.3 million sale and a $10.5 million sale, which can pressure investor sentiment because of the size and frequency of the transactions. Article Title
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
